Pharmas Urged To Take Committed Steps Along The IDN Pathway
Integrated Delivery Networks can have a major influence on the drug classes prescribed by physicians affiliated with their network. IMS urges pharma companies to approach these increasingly important partners in health care delivery with strategies that are significantly different than those they've used in the past.
You may also be interested in...
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.